HON vs NKE: Which Is the Better Buy?

Side-by-side comparison of Honeywell International Inc. and NIKE, Inc. β€” fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-04-11.
Honeywell International Inc. Β· Industrials
$235.04
-9.9% upside to fair value
Med Conviction Grade B
VS
NIKE, Inc. Β· Consumer Cyclical
$42.62
+45.5% upside to fair value
Med Conviction Grade B+
QuantHub Verdict
NKE has more upside to fair value (+45.5%). HON trades at a lower forward P/E (22.3x). These are model outputs β€” not personalized investment advice. See all research β†’
Valuation & Fundamentals
Metric HON NKE
Current Price $235.04 $42.62
Fair Value Estimate $211.73 $62.00
Upside to Fair Value -9.9% +45.5%
Market Cap $149.4B $63.0B
Forward P/E 22.3x 27.9x
EV / EBITDA 16.9x 20.7x
Price / Sales 4.0x 1.4x
Price / FCF 27.7x 19.4x
Revenue Growth YoY -2.7% -9.8%
Gross Margin 36.9% 42.7%
Operating Margin 17.7% 8.0%
Return on Equity 33.28% 24.4%
Dividend Yield 1.92% 3.8%
FCF Yield 3.61% 5.2%
Analyst Consensus Buy Buy
Investment Thesis
HON β€” Honeywell International Inc.
Honeywell is a diversified industrial conglomerate in the final stages of a transformative three-way separation into Honeywell Aerospace, Solstice Advanced Materials, and a retained Automation entity, targeting Q3 2026 completion. The business generated 33% ROE and $5.4B in free cash flow on $37.4B revenue in FY2025, supported by a record $37B backlog with 23% organic order growth in Q4. At $235 …
NKE β€” NIKE, Inc.
Nike is the world's largest athletic footwear and apparel company with $46.3B in FY2025 revenue, operating across 190+ countries with the Nike, Jordan, and Converse brands. The stock trades near its 9-year low at $42.62 after an 11% single-day crash following a Q3 FY2026 earnings report that showed 35% net income decline and weak Q4 guidance calling for a further 2-4% revenue decline. FY2025 reve…
Accumulation Zones
Metric HON NKE
Zone Low $158.80 $44.00
Zone High $179.97 $50.00
In Buy Zone? No Yes
← HON Research    NKE Research β†’    All Research